Celldex Therapeutics, Inc.
CLDX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000744218
No open-market purchases or sales by Celldex Therapeutics, Inc. insiders were filed in the last 90 days; 253 institutions reported holding it in 13F filings for Q2 2026, worth $3.16B in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Celldex Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Of which not filed for Q3 2023 | Q3 2023 | Change |
|---|---|---|---|---|
| Holders | 150 | 1 | 144 | −5 |
| Shares | 50.2M | 1.79M | 50.6M | +2.18M (+4.5%) |
| Value | $1.70B | $60.9M | $1.39B | −$250.3M (−15.2%) |
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (15)
Institutions that held Celldex Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Pictet Asset Management Holding SA | 1,850,970 | $50.9M | 0.06% |
| Polar Asset Management Partners Inc. | 132,400 | $3.64M | 0.09% |
| Balyasny Asset Management LLC | 27,415 | $754.5K | 0.00% |
| ExodusPoint Capital Management, LP | 26,434 | $727.0K | 0.01% |
| HRT Financial LP | 21,605 | $594.0K | 0.01% |
| Connor, Clark & Lunn Investment Management Ltd. | 18,155 | $499.6K | 0.00% |
| Moody Aldrich Partners LLC | 14,687 | $404.2K | 0.08% |
| Engineers Gate Manager LP | 13,653 | $375.7K | 0.01% |
| Caption Management, LLC | 13,000 | $357.8K | 0.05% |
| XTX Topco Ltd | 11,159 | $307.1K | 0.05% |
| Centiva Capital, LP | 9,727 | $267.7K | 0.01% |
| Close Asset Management Ltd | 133 | $4.00K | 0.00% |
| Highlander Capital Management, LLC | 20 | $1.00K | 0.00% |
| CWM, LLC | 26 | $1.00K | 0.00% |
| Householder Group Estate & Retirement Specialist, LLC | 11 | $303 | 0.00% |
Sold out (20)
Institutions that held Celldex Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Fred Alger Management, LLC | 165,317 | $5.61M |
| Prudential Financial Inc | 57,601 | $1.95M |
| ClariVest Asset Management LLC | 33,894 | $1.15M |
| Franklin Resources Inc | 23,003 | $780.5K |
| Two Sigma Investments, LP | 18,423 | $625.1K |
| Soleus Capital Management, L.P. | 13,600 | $461.4K |
| Squarepoint Ops LLC | 11,719 | $397.6K |
| Cubist Systematic Strategies, LLC | 11,460 | $388.8K |
| Silverarc Capital Management, LLC | 10,000 | $339.3K |
| Values First Advisors, Inc. | 7,560 | $256.5K |
| AQR Capital Management LLC | 6,835 | $231.9K |
| ProShare Advisors LLC | 6,043 | $205.0K |
| HM Payson & Co | 960 | $32.6K |
| Leonteq Securities AG | 500 | $17.0K |
| Simplex Trading, LLC | 491 | $16.0K |
| NewSquare Capital LLC | 115 | $3.90K |
| Lindbrook Capital, LLC | 54 | $1.83K |
| Bell Investment Advisors, Inc | 23 | $781 |
| Venturi Wealth Management, LLC | 5 | $170 |
| Northwestern Mutual Wealth Management Co | 1 | $34 |
Not filed for Q3 2023 yet (1)
Institutions that held Celldex Therapeutics, Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Pictet Asset Management SA | 1,794,048 | $60.9M |